Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Gajanan Sapkal and Priya Abraham.
Gajanan Sapkal
Connection Strength
2.572
Priya Abraham
  1. Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine. J Travel Med. 2021 10 11; 28(7).
    View in: PubMed
    Score: 0.243
  2. Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals. J Travel Med. 2021 10 11; 28(7).
    View in: PubMed
    Score: 0.243
  3. Performance assessment of seven SARS-CoV-2 IgG enzyme-linked immunosorbent assays. J Med Virol. 2021 Dec; 93(12):6696-6702.
    View in: PubMed
    Score: 0.240
  4. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. J Travel Med. 2021 Jun 01; 28(4).
    View in: PubMed
    Score: 0.237
  5. Respiratory virus detection among the overseas returnees during the early phase of COVID-19 pandemic in India. Indian J Med Res. 2020 05; 151(5):486-489.
    View in: PubMed
    Score: 0.220
  6. Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG. Indian J Med Res. 2020 May; 151(5):444-449.
    View in: PubMed
    Score: 0.220
  7. Authors' response. Indian J Med Res. 2020 05; 151(5):496.
    View in: PubMed
    Score: 0.220
  8. Laboratory preparedness for SARS-CoV-2 testing in India: Harnessing a network of Virus Research & Diagnostic Laboratories. Indian J Med Res. 2020 Feb & Mar; 151(2 & 3):216-225.
    View in: PubMed
    Score: 0.216
  9. First isolation of SARS-CoV-2 from clinical samples in India. Indian J Med Res. 2020 Feb & Mar; 151(2 & 3):244-250.
    View in: PubMed
    Score: 0.216
  10. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. J Travel Med. 2021 10 11; 28(7).
    View in: PubMed
    Score: 0.061
  11. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. iScience. 2021 Apr 23; 24(4):102298.
    View in: PubMed
    Score: 0.058
  12. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021 07; 21(7):950-961.
    View in: PubMed
    Score: 0.058
  13. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Commun. 2021 03 02; 12(1):1386.
    View in: PubMed
    Score: 0.058
  14. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021 05; 21(5):637-646.
    View in: PubMed
    Score: 0.058
  15. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. iScience. 2021 Feb 19; 24(2):102054.
    View in: PubMed
    Score: 0.058
  16. Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):82-87.
    View in: PubMed
    Score: 0.056
  17. Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection. Indian J Med Res. 2020 May; 151(5):479-482.
    View in: PubMed
    Score: 0.055
  18. Genomic analysis of SARS-CoV-2 strains among Indians returning from Italy, Iran & China, & Italian tourists in India. Indian J Med Res. 2020 Feb & Mar; 151(2 & 3):255-260.
    View in: PubMed
    Score: 0.054
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.